Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Trial Profile

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LXS 196 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Skin cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors IDEAYA Biosciences
  • Most Recent Events

    • 20 Nov 2019 According to an IDEAYA Biosciences media release, 27 total patients enrolled in the Phase 1 dose escalation portion of the study, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort.
    • 20 Nov 2019 According to an IDEAYA Biosciences media release, the company is on-track for Phase 2 dose-selection and expansion into the potential registration-enabling portion of the trial for MUM in December 2019. Interim data with efficacy is expected in Q2/Q3 2020. Additional patients enrolled post-October 28, 2019 will better characterize tolerability and pharmacokinetics for Phase 2 dose selection.
    • 20 Nov 2019 According to an IDEAYA Biosciences media release, data from phase I portion of the study were presented at the 16th International Congress for the Society for Melanoma Research (SMR Congress) 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top